PDS Biotechnology Corporation [NASDAQ: PDSB] closed the trading session at $3.85 on 07/30/20. The day’s price range saw the stock hit a low of $3.49, while the highest price level was $3.90. The company report on July 30, 2020 that PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executive Officer, Michael King, Interim Chief Financial Officer, and Dr. Lauren Wood, Chief Medical Officer will host a conference call to review the financial results and provide a business update.
The conference call is scheduled to begin at 8:00 am ET on Thursday, August 13, 2020. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company’s corporate website at www.pdsbiotech.com.
The stocks have a year to date performance of 45.28 percent and weekly performance of 1.05 percent. The stock has been moved at 46.95 percent over the last six months. The stock has performed 91.54 percent around the most recent 30 days and changed 305.26 percent over the most recent 3-months.
If compared to the average trading volume of 1.73M shares, PDSB reached to a volume of 1142156 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about PDS Biotechnology Corporation [PDSB]:
Alliance Global Partners have made an estimate for PDS Biotechnology Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 27, 2020. While these analysts kept the previous recommendation, Noble Capital Markets raised their target price to Outperform. The new note on the price target was released on March 09, 2020, representing the official price target for PDS Biotechnology Corporation stock. Previously, the target price had yet another raise to $10, while Chardan Capital Markets analysts kept a Buy rating on PDSB stock.
The Average True Range (ATR) for PDS Biotechnology Corporation is set at 0.53 The Price to Book ratio for the last quarter was 1.99, with the Price to Cash per share for the same quarter was set at 1.29.
PDSB stock trade performance evaluation
PDS Biotechnology Corporation [PDSB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.05. With this latest performance, PDSB shares gained by 91.54% in over the last four-week period, additionally plugging by 46.95% over the last 6 months – not to mention a drop of -40.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PDSB stock in for the last two-week period is set at 65.38, with the RSI for the last a single of trading hit 65.25, and the three-weeks RSI is set at 65.36 for PDS Biotechnology Corporation [PDSB]. The present Moving Average for the last 50 days of trading for this stock 2.00, while it was recorded at 3.72 for the last single week of trading, and 1.91 for the last 200 days.
PDS Biotechnology Corporation [PDSB]: An insightful look at the core fundamentals
Return on Total Capital for PDSB is now -74.68, given the latest momentum, and Return on Invested Capital for the company is -33.70. Return on Equity for this stock declined to -33.70, with Return on Assets sitting at -27.60.
Reflecting on the efficiency of the workforce at the company, PDS Biotechnology Corporation [PDSB] managed to generate an average of -$349,930 per employee.PDS Biotechnology Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.90 and a Current Ratio set at 5.90.
Earnings per share (EPS) analysis for PDS Biotechnology Corporation [PDSB] stock
With the latest financial reports released by the company, PDS Biotechnology Corporation posted -8.2/share EPS, while the average EPS was predicted by analysts to be reported at -10.52/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 22.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PDSB.
PDS Biotechnology Corporation [PDSB]: Insider Ownership positions
There are presently around $6 million, or 10.80% of PDSB stock, in the hands of institutional investors. The top three institutional holders of PDSB stocks are: FEDERATED HERMES, INC. with ownership of 384,000, which is approximately New of the company’s market cap and around 3.80% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 309,621 shares of the stock with an approximate value of $1.19 million in PDSB stocks shares; and WORTH VENTURE PARTNERS, LLC, currently with $0.62 million in PDSB stock with ownership of nearly New of the company’s market capitalization.
Positions in PDS Biotechnology Corporation stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 16 institutional holders increased their position in PDS Biotechnology Corporation [NASDAQ:PDSB] by around 1,129,837 shares. Additionally, 5 investors decreased positions by around 18,907 shares, while 13 investors held positions by with 503,544 shares. The mentioned changes placed institutional holdings at 1,652,288 shares, according to the latest SEC report filing. PDSB stock had 12 new institutional investments in for a total of 898,297 shares, while 2 institutional investors sold positions of 15,780 shares during the same period.